MedTech Startups from Singapore to Watch in 2025

MedTech Startups from Singapore to Watch in 2025

Singapore’s thriving MedTech ecosystem is home to some of the world’s most innovative healthcare startups. Positioned at the intersection of advanced technology and medicine, these companies are not just transforming healthcare in Asia but are also making a significant global impact. Below, we spotlight Singapore-based startups from four key areas of MedTech innovation: targeted therapies, data-driven care delivery, precision diagnostics, and surgical robotics. Notably, many of these companies will be proudly representing Singapore at the SG Innovation Enterprise Showcase 2025, which will take place in San Francisco on January 15, 2025, further solidifying the nation’s position as a global MedTech hub.

About the SG Innovation Enterprise Showcase 2025

The 3rd SG Innovation Enterprise Showcase is happening on 15 January 2025 at the San Francisco Marriott Marquis, coinciding with the week of the J.P. Morgan Annual Healthcare Conference. This event provides a unique platform for Singapore’s most innovative startups to present their groundbreaking technologies to a global audience. Attendees will have the opportunity to exchange ideas, connect with leading innovators, and build valuable partnerships with investors and industry leaders shaping the future of healthcare.

The panel discussion will bring together prominent industry leaders and innovators to explore Singapore’s growing role as a global MedTech hub. Attendees can expect insights into investment trends, collaboration opportunities, and the dynamic ecosystem driving biomedical innovation in the region

Panelists:

• Amy Schulman, Managing Partner, Polaris Partners
• Ansbert Gadicke, Managing Partner, MPM Bioimpact
• Alessandro Falcone, Head, JLABS Singapore, Johnson & Johnson
• Hugo Saavedra, Co-founder & CEO, KYAN Technologies
• Irene Cheong, Assistant CEO, A*STAR (Moderator)

Data-Driven Care Delivery: Empowering Smarter Healthcare

Singaporean startups are leveraging data analytics, artificial intelligence (AI), and machine learning to transform the healthcare landscape, enhancing both patient outcomes and operational efficiency. By integrating advanced MedTech solutions and data-driven approaches into care delivery, these companies are enabling smarter decision-making, personalized treatment plans, and streamlined workflows for healthcare providers.

Startups in Singapore are creating innovative solutions to harness vast amounts of patient data collected from electronic health records (EHRs), wearables, and other medical devices. For example, predictive analytics tools are being used to anticipate patient needs, detect early signs of chronic diseases, and optimize resource allocation. AI-powered platforms are also facilitating real-time monitoring, helping healthcare professionals identify critical changes in patient conditions and intervene more effectively.

Additionally, these startups are driving the development of precision medicine by utilizing genomic data and advanced algorithms to tailor treatments to individual patients. Beyond clinical care, data-driven innovations are being applied to improve hospital operations, reduce waiting times, and enhance the overall patient experience. With Singapore’s robust digital infrastructure and focus on innovation, these advancements are positioning the country as a leader in smart healthcare solutions.

Credit: AeviceMD website

Focus: Respiratory Health Monitoring
Website: www.aevice.com

About:

Aevice Health, founded in 2016 as a spin-off from Nanyang Technological University in Singapore, is a MedTech company dedicated to revolutionizing the management of chronic respiratory diseases. The company develops non-invasive, AI-powered wearable devices that enable early detection of cardiopulmonary abnormalities, facilitating real-time health tracking for both adults and children.

Their flagship products include AeviceMD, a wearable stethoscope that analyzes lung sounds to monitor patients, diagnose coughs or wheezes, and track therapy responses, and AireSone Junior, a smart wearable designed to monitor a child’s breathing rate and heart rate during sleep.

In August 2024, Aevice Health secured SGD 7 million in seed funding to further its mission of providing accessible respiratory care globally.

The company’s leadership team includes CEO Adrian Ang and CTO Rex Tan, who are committed to empowering patients with chronic respiratory diseases to take control of their health.

Aevice Health’s innovative solutions have positioned it as a key player in the MedTech industry, contributing significantly to advancements in remote patient monitoring and respiratory health management.

AI Integration:

Aevice Health integrates AI into its wearable devices to monitor and manage chronic respiratory diseases. Their flagship device, AeviceMD, uses AI algorithms to analyze lung sounds, detect abnormalities like wheezing, and provide real-time data for early intervention (Aevice Health). Similarly, AireSone Junior employs AI to track breathing and heart rate in children, sending instant alerts to caregivers when irregularities are detected (YourStory).

These AI-driven solutions enable precise remote monitoring, reduce hospital visits, and offer actionable insights to healthcare providers. Continuous machine learning also enhances the accuracy and efficiency of their devices, demonstrating innovation in respiratory care (Preqin).

Achievements:

Aevice Health has achieved significant milestones, including HSA approval in Singapore and FDA clearance in the U.S. for its AI-powered AeviceMD device, which enables remote respiratory monitoring (Aevice Health). The AeviceMD also won the CES 2023 Innovation Award for its groundbreaking contributions to digital health. Additionally, Aevice Health has partnered with Toho Holdings in Japan to introduce its innovative respiratory solutions to the Japanese market (MobiHealthNews).

Focus: Chronic Disease Predictive Analytics for Healthcare
Website: www.meshbio.com

About:

Mesh Bio, founded in 2018 by Dr. Andrew Wu and Arsen Batagov, is a Singapore-based health deep tech startup specializing in predictive analytics for chronic disease management. Their flagship product, the DARA® Health Intelligence Platform, integrates multidimensional patient data to provide actionable insights, enhancing clinical decision support and patient engagement.

Arsen Batagov and Dr. Andrew Wu, Co-Founders at Mesh Bio. 

In October 2023, Mesh Bio secured an undisclosed investment from East Ventures to further develop its digital twin technologies and expand services across Southeast Asia, including Indonesia, Malaysia, and the Philippines.

By January 2024, the company raised an additional US$3.5 million in Series A funding led by East Ventures, aiming to scale its digital twin technologies and enhance chronic disease management solutions in the region.

Mesh Bio’s innovative approach addresses the growing burden of chronic diseases in Southeast Asia, providing healthcare providers with tools to improve patient outcomes through data-driven care delivery.

AI Integration:

Mesh Bio utilizes artificial intelligence (AI) to enhance chronic disease management through predictive analytics and clinical decision support. Their AI-driven platform, DARA®, analyzes multidimensional patient data to provide actionable insights for healthcare providers, improving patient engagement and health outcomes.

In collaboration with MultiOmic Health, Mesh Bio employs AI-based computational biology models to integrate genomic, proteomic, and metabolomic data. This approach aims to develop precision therapeutics and diagnostics for chronic metabolic diseases, facilitating personalized patient care.

Additionally, Mesh Bio’s HealthVector® Diabetes, a digital twin technology, uses AI to predict the 3-year onset risk of chronic kidney disease in patients with type 2 diabetes. This tool assists clinicians in prioritizing and intensifying treatments to delay disease progression.

Through these AI-driven solutions, Mesh Bio is advancing personalized medicine and improving outcomes for patients with chronic diseases.

Achievements:

Mesh Bio’s HealthVector® Diabetes, a digital twin technology predicting the 3-year onset risk of chronic kidney disease in type 2 diabetes patients, received HSA approval in Singapore in 2023. The company also secured $3.5 million in Series A funding in early 2024, led by East Ventures, to scale its technologies and expand its reach across Southeast Asia, including Indonesia and the Philippines. Partnerships with PT Pramita in Indonesia and MultiOmic Health have further enhanced their capabilities in preventive healthcare and precision medicine.

Additionally, Mesh Bio’s participation in the international accelerator program Startup Creasphere marked a significant recognition of its innovative digital health solutions. Collaborations with key healthcare stakeholders have enabled Mesh Bio to apply its AI-driven platform, DARA®, to provide actionable insights for chronic disease care. These achievements position Mesh Bio as a leader in leveraging predictive analytics to improve clinical outcomes and address the growing burden of chronic diseases globally.

Focus: Clinical Trial Acceleration
Website: www.oncoshot.com

About:

Oncoshot is an innovative real-time health insights exchange platform that bridges healthcare providers and the healthcare industry, facilitating secure data exchange and connecting experts with crucial insights derived from real-time patient data. At its core, Oncoshot’s in-premise medical Large Language Model (LLM) empowers hospitals to analyze raw healthcare data and generate actionable insights. These insights inform industry decision-making, leading to accelerated patient enrollment into clinical trials and reduced drug development costs, ultimately expediting the delivery of potentially life-saving therapies to patients.

Founded by Dr. Huren Sivaraj, a board-accredited medical oncologist, and Ruslan Enikeev, an experienced engineer and data scientist, Oncoshot addresses information gaps that prevent cancer patients from fully accessing treatment options. The company leads initiatives like Project Enhanced Clinical Trial Initiation, Screening, and Enrollment (Project EISE), Singapore’s first nationwide collaboration connecting cancer patients, healthcare professionals, and pharmaceutical companies within one ecosystem. With a presence in Singapore, Australia, India, and Taiwan, Oncoshot continues to expand its partnerships to better serve the global community.

AI Integration:

Achievements:

Oncoshot has achieved significant milestones within its ecosystem, including partnerships with:

• 40+ hospitals and clinical research networks
• 10 pharmaceutical companies and CROs
• 1081 active clinical trials
• 300k+ patients contributing to their platform

Targeted Therapies and Drug Discoveries: Innovating Precision Medicine

Singapore’s targeted therapy sector is revolutionizing personalized medicine by focusing on treatments tailored to individual patients’ genetic and molecular profiles. This approach leverages advanced scientific techniques to create therapies that directly target the underlying causes of diseases, reducing side effects and improving effectiveness. With cutting-edge research in areas such as immunotherapy, gene editing, and cellular therapy, Singapore is at the forefront of drug discoveries that address complex conditions like cancer, rare genetic disorders, and autoimmune diseases. By integrating precision medicine with innovative technologies, these companies are not only improving patient outcomes but also setting new benchmarks in global healthcare innovation.

Focus: Gene and Cellular Therapy
Website: www.tikvaallocell.com

About: Tikva Allocell, founded in 2023 and headquartered in Singapore, is a preclinical-stage biotech company focused on developing “off-the-shelf” T cell therapies for solid tumors. Using its proprietary, IP-protected platform based on allogeneic Epstein-Barr Virus-Specific T cells (ALLO EBVST), Tikva Allocell aims to deliver safe, effective, and affordable cancer treatments.

The founding team comprises key opinion leaders in cell and gene therapy, including Dr. Ivan Horak (Founder & CEO), Professor Malcolm Brenner (Co-Founder), Professor Cliona Rooney (Co-Founder), and Professor Helen Heslop (Co-Founder). In March 2024, Tikva Allocell secured exclusive licensing of novel cell therapy technologies from Baylor College of Medicine to advance its pipeline against solid tumors. The company has also established strategic partnerships with academic institutions in the U.S. and Singapore, including a joint laboratory with A*STAR’s Institute of Molecular and Cell Biology.

Guided by the mission to inspire hope today for a better tomorrow, the company is advancing innovative therapies to drive the next breakthrough in cancer care.

Achievements:

• In March 2024, the company secured exclusive licensing of novel cell therapy technologies from Baylor College of Medicine, advancing its pipeline against solid tumors.
• The following month, Tikva Allocell joined the Johnson & Johnson Innovation – JLABS community, enhancing its research and development capabilities.
• In September 2024, Dr. Ivan D. Horak, CEO and Founder of Tikva Allocell, received the Lifetime Achievement Award at the Asia Pacific Cell & Gene Therapy Excellence Awards, recognizing his contributions and leadership in the cell and gene therapy field.
• Tikva Allocell’s scientists have published peer-reviewed papers on promising off-the-shelf CAR T cell therapies targeting B7-H3 positive solid tumors, enhancing allogeneic T-cell persistence and efficacy with overexpression of engineered SERPINB9, and novel OX40 and 4-1BB derived spacers enhancing CD30 CAR activity and safety in CD30 positive lymphoma models.

Focus: Cellular Immunotherapies
Website: www.biosyngen.com

About: Biosyngen, founded in Singapore in 2016, is a leading immuno-oncology company focused on developing cutting-edge cell therapies to address unmet needs in cancer treatment. Leveraging advanced research and global partnerships, Biosyngen’s product pipeline includes CAR-T, TCR-T, and TIL therapies targeting cancers such as nasopharyngeal, lung, liver, and gastrointestinal cancers. Its flagship product, BRG01, designed for nasopharyngeal carcinoma, has received Fast Track Designation from the U.S. FDA.

With dual R&D and GMP manufacturing facilities in Singapore and Guangzhou, Biosyngen combines innovation with large-scale production capabilities. Recent expansions, including a new 1,500-square-meter facility in Singapore, aim to enhance its global reach while creating hundreds of jobs. Through its pioneering work in immunotherapy, Biosyngen is committed to giving cancer patients a second chance and contributing to the advancement of the global biotech ecosystem.

Achievements:

BioSyngen has developed a proprietary platform for expanding tumor-infiltrating lymphocytes (TILs) from biopsy samples, achieving the production of 10¹¹ cells within four weeks. The company has also established a stable gene modification platform that reprograms TIL metabolism, enhancing activity and sustained antitumor efficacy by expressing membrane anchor proteins. This approach significantly improves antitumor efficacy (without IL-2 co-injection) with no notable toxicity observed. Additionally, BRG01, a CAR-T therapy targeting the Epstein-Barr virus (EBV) antigen, completed Phase I clinical trial enrollment in January 2024,  Within less than a year, all participants were treated, demonstrating a strong safety profile and encouraging initial efficacy results.

With eight clinical trial approvals in the United States and China, BioSyngen is among the few biotechnology companies capable of simultaneously advancing CAR-T, TCR-T, and TIL technologies into in-human trials.

BRG01, a CAR-T therapy targeting the Epstein-Barr virus (EBV) antigen, completed Phase I clinical trial enrollment in January 2024. Within less than a year, all participants were treated, demonstrating a strong safety profile and encouraging initial efficacy results.

Focus: Targeted Immunotherapies
Website: https://www.ai-therapies.com/

About: Based in Singapore, Ananda Immunotherapies is a clinical-stage biotechnology company currently operating in stealth mode. A spin-out from Duke-NUS Medical School and SingHealth in Singapore, Ananda is dedicated to pioneering advancements in immune tolerance. Its innovative science and therapeutic pipeline focus on cell-based strategies to reverse autoimmunity and restore immune system balance. Unlike traditional treatments that rely on immune suppression, Ananda’s approach aims to address the root cause of autoimmunity by promoting long-term immune regulation.

AI Integration: Ananda Immunotherapies, founded by Professor Salvatore Albani, a Professor of Medicine at Duke-NUS Medical School in Singapore, utilizes high-dimensional data and artificial intelligence (AI) to study immune processes as interconnected components within a network, referred to as the “immunome.” This cutting-edge approach facilitates the development of cell-based, network-wide therapies designed to restore immune balance, offering the potential to reverse and even cure autoimmune diseases.

Precision Diagnostics: Early and Accurate Detection

Singapore is making significant strides in precision diagnostics, particularly in cancer care, with innovative startups at the forefront. By combining AI, molecular diagnostics, and genomics, these companies are revolutionizing early detection and diagnosis, enabling more accurate and timely interventions.

Startups like Lucence and MiRXES are developing cutting-edge solutions such as liquid biopsies and blood-based tests to identify cancer at its earliest stages. Qritive are leveraging AI-powered tools to analyze pathology slides with precision, improving the speed and accuracy of cancer diagnosis. Their technology supports clinicians in detecting cancers earlier and streamlining workflows, ultimately enhancing patient outcomes. These efforts showcase Singapore’s growing leadership in precision healthcare, offering hope for better patient outcomes and cancer management.

Focus: Liquid Biopsy for Cancer Detection
Website: www.lucence.com

About:

Lucence Diagnostics is a Singapore-based precision oncology company that was spun off from the Agency for Science, Technology and Research (A*STAR) in 2016. Specializing in liquid biopsies and molecular diagnostics, Lucence focuses on early cancer detection and personalized treatment. Its proprietary technologies enable the development of non-invasive blood-based tests to identify cancer-specific genetic mutations and biomarkers, empowering clinicians to detect cancers at early stages and tailor treatment plans to individual patients effectively.

Their flagship product, LiquidHALLMARK, is a liquid biopsy test that detects multiple cancer types and actionable mutations from a single blood draw. By combining advanced genomic analysis and AI-driven insights, Lucence is transforming cancer care, improving early detection, and supporting more effective treatment decisions globally.

AI Integration:

Lucence leverages AI to enhance its precision oncology solutions, particularly in its flagship liquid biopsy test, LiquidHALLMARK. AI plays a critical role in analyzing complex genomic data, identifying cancer-specific genetic mutations, and extracting actionable insights from patient samples.

The company’s AI-driven platform improves the accuracy and speed of detecting mutations and biomarkers, which are crucial for early cancer detection and personalized treatment. By combining advanced AI algorithms with next-generation sequencing, Lucence ensures its diagnostic tools deliver highly reliable and precise results, empowering clinicians to make informed decisions and improving outcomes for cancer patients.

Achievements:

Lucence has made significant strides in precision oncology, marked by its development of LiquidHALLMARK, the world’s first blood-based test capable of detecting multiple cancer types and actionable mutations from a single blood draw. The company’s technology has received global recognition, including the U.S. FDA’s Breakthrough Device Designation, emphasizing its potential to revolutionize cancer diagnostics. Lucence has formed strategic partnerships with leading institutions, such as Stanford University, to advance research and innovation in precision medicine. Its solutions have been deployed globally, supporting thousands of patients in Asia, the U.S., and Europe. With $20 million in Series A funding, led by Temasek Holdings and Pavilion Capital, Lucence has scaled its operations to expand the reach of its non-invasive diagnostic tools. Recognized as a leader in molecular diagnostics, Lucence continues to set new benchmarks in early cancer detection and personalized care.

Focus: AI-Powered Pathology
Website: www.qritive.com

About:

Qritive is a Singapore-based company specializing in AI-powered digital pathology solutions to improve cancer diagnosis. Founded in 2017, its flagship platform, Pantheon™, uses AI to streamline pathology workflows, enabling rapid whole slide image analysis and seamless integration with Laboratory Information Systems (LIS) and Electronic Medical Records (EMR).

The company collaborates with leading partners like Roche to enhance diagnostic accuracy and efficiency, reducing turnaround times and improving patient outcomes. Backed by investors such as MassMutual Ventures and SEEDS Capital, Qritive continues to innovate in digital pathology, supporting pathologists with advanced AI tools for better disease management.

AI Integration:

Qritive leverages artificial intelligence (AI) to transform pathology workflows and improve cancer diagnostics. Their flagship platform, Pantheon™, uses AI algorithms to analyze high-resolution whole-slide pathology images, detecting abnormalities, classifying tissue samples, and identifying cancer markers with high precision. This automation reduces the time pathologists spend on routine tasks, allowing them to focus on complex cases and ensuring faster and more accurate diagnoses.

Qritive’s AI integrates seamlessly with Laboratory Information Systems (LIS) and Electronic Medical Records (EMR), streamlining case management and diagnostic workflows. The AI also assists in tumor grading, quantifying biomarkers, and identifying disease patterns, which are critical for clinical decision-making. By collaborating with partners like Roche’s navify Digital Pathology, Qritive enhances the accessibility and scalability of its AI-powered tools, making them valuable for healthcare providers and research institutions. Through these innovations, Qritive’s AI significantly improves diagnostic efficiency, accuracy, and patient outcomes.

Achievements:

Qritive has secured $7.5 million in funding from investors like MassMutual Ventures and Exfinity Venture Partners, fueling its growth in AI-driven diagnostics. It achieved CE marking for its Pantheon™ platform and Class C IVD certification from Singapore’s HSA for its QAi Prostate Dx module, enabling deployment in key markets. Strategic partnerships in India with Metropolis Healthcare and Rajiv Gandhi Cancer Institute have further expanded its reach. Additionally, Qritive earned ISO/IEC 27001:2022 certification, showcasing its commitment to data security and quality in healthcare.

Surgical Robotics: Enhancing Precision in the Operating Room

Singapore’s surgical robotics innovators are redefining minimally invasive procedures with advanced technologies that improve precision, safety, and outcomes. Startups like Vivo Surgical and NousQ are at the forefront of this transformation, developing groundbreaking solutions tailored to patient and surgeon needs.

Vivo Surgical focuses on next-generation robotic-assisted surgical systems, including its proprietary KLARO™ platform, designed for precision and adaptability in minimally invasive surgeries. Similarly, NousQ has developed the automated CLiKX device, a robotic-assisted system for ear surgeries, which simplifies the process of tympanostomy tube insertion, particularly in children. These innovations highlight Singapore’s leadership in surgical robotics, setting new benchmarks for healthcare technology.

Focus: Robotic Ear Surgery
Website: www.nousq.com

About:

NousQ, a Singapore-based medtech startup founded in 2021, specializes in developing innovative healthcare solutions. Its flagship product, CLiKX, is an automated device for tympanostomy tube insertion, designed to simplify and improve ear surgeries, particularly for children. Developed with over SGD 5 million in research grants from A*STAR and the National Research Foundation, NousQ has secured USD 1.2 million in seed funding and is advancing clinical trials for regulatory approval. With a mission to enhance global healthcare access, NousQ combines cutting-edge technology with a patient-centric approach to improve outcomes worldwide.

Achievements:

NousQ’s flagship product, CLiKX, has earned widespread recognition for its innovation in ear tube insertion. The company won the MedTech Innovator APAC Challenge 2022 Grand Prize, receiving US$175,000, and was also a winner of the Medtronic APAC Innovation Challenge, securing US$170,000.

Founder and CEO, Dr. Lynne Lim, was awarded the Cartier Women’s Initiative Science & Technology Pioneer Award 2024, highlighting NousQ’s leadership in medtech innovation. Additionally, NousQ was recognized as a Hello Tomorrow Deep Tech Pioneer and ranked among the top 12 startups in the SLINGSHOT 2022 Health & Biomedical category, solidifying its position as a key player in healthcare innovation.

Focus: Minimally Invasive Robotic Surgery
Website: https://www.vivo-surgical.com/

About:

Vivo Surgical, founded in 2018 in Singapore, develops innovative surgical technologies and robotics to enhance patient outcomes. Its flagship product, KLARO®, provides in vivo surgical LED lighting for better visibility during procedures. The company is ISO 13485 certified and has received US FDA approval, CE marking, and HSA certification. Vivo Surgical collaborates globally with healthcare and research partners, contributing to advancements in minimally invasive surgery and improving surgical standards worldwide.

Achievements:

Vivo Surgical has achieved significant recognition for its contributions to surgical innovation. The company was honored with the WIPO Global Award 2024, placing it among the top nine companies globally for excellence in innovation and intellectual property management. In 2022, Vivo Surgical received the WIPO-IPOS IP for Innovation Award, being the only early-stage startup recognized for its outstanding growth through effective use of intellectual property. Additionally, it was selected as a top finalist in the MedTech Innovator Asia Pacific Competition 2023, showcasing its impact on advancing medtech solutions.

Singapore: A Global MedTech Hub

These startups exemplify Singapore’s position as a global MedTech leader. By leveraging AI, fostering innovation, and addressing critical healthcare challenges, they are transforming patient care on a global scale. Many of these companies will further showcase their breakthroughs at the prestigious SG Innovation Enterprise Showcase 2025 in San Francisco underscoring their impact and global relevance.

At Scopic, we celebrate their achievements and stand ready to collaborate with visionaries shaping the future of medicine. If you’re a MedTech innovator looking for cutting-edge software solutions, let’s build the future of healthcare together.